Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 8Burkitt Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 3Smoldering Multiple Myeloma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Meningioma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Recurrence × dexamethasone 21-phosphate × Clear all
NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1 Recruiting
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡